Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glulisine Regimens in Type 2 Diabetes
NCT00135057Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in Hemoglobin A1c at 24 weeks. Started Apr 2004; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00135057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135057.